Presence of particular types of CH (mutations in DNA repair genes and TP53) may predispose patients to the development of therapy-related myeloid neoplasms [99], predict outcomes after autologous stem cell transplantation [100], and provide insights into the tumor microenvironment and response to immunotherapy [101,102]. Here, TP53 is linked to myeloid neoplasm.